🔴 HCW Biologics is trading 9.69% down in pre-market after wider losses and going-concern doubt

HCW Biologics is trading 9.69% down at $2.28 after its August 14, 2026, second-quarter report highlighted a wider net loss and substantial doubt about continuing as a going concern without additional funding.

• Quarterly net losses totaled $5.2 million despite licensing revenue growth.
• Shares declined 8.38% on August 14 and continued lower afterward.
• Broader market weakness is adding pressure.